| dc.contributor.advisor | Liersch, Torsten PD Dr. | |
| dc.contributor.author | Styczen, Hanna | |
| dc.date.accessioned | 2013-08-26T09:10:58Z | |
| dc.date.available | 2014-07-08T22:50:05Z | |
| dc.date.issued | 2013-08-26 | |
| dc.identifier.uri | http://hdl.handle.net/11858/00-1735-0000-0001-BB32-2 | |
| dc.identifier.uri | http://dx.doi.org/10.53846/goediss-4006 | |
| dc.language.iso | deu | de |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | |
| dc.subject.ddc | 610 | de |
| dc.title | Der HER-2-Status im lokal fortgeschrittenen Rektumkarzinom: Positivitätsrate, mögliche prädiktive und prognostische Bedeutung | de |
| dc.type | doctoralThesis | de |
| dc.title.translated | Frequency of HER-2 positivity in rectal cancer and prognosis | de |
| dc.contributor.referee | Liersch, Torsten PD Dr. | |
| dc.date.examination | 2013-11-12 | |
| dc.description.abstracteng | In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3 or silver in situ hybridization ratios of ≥2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P=0.1) and a benefit in CSS (P=0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P<0.00001) and R status (P=0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials. | de |
| dc.contributor.coReferee | Ströbel, Philipp Prof. Dr. | |
| dc.subject.ger | HER-2-Status | de |
| dc.subject.ger | Rektumkarzinom | de |
| dc.subject.eng | HER-2 | de |
| dc.subject.eng | rectal cancer | de |
| dc.identifier.urn | urn:nbn:de:gbv:7-11858/00-1735-0000-0001-BB32-2-5 | |
| dc.affiliation.institute | Medizinische Fakultät | de |
| dc.subject.gokfull | Chirurgie - Allgemein- und Gesamtdarstellungen (PPN619875968) | de |
| dc.description.embargoed | 2014-07-08 | |
| dc.identifier.ppn | 766328937 | |